KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Net Cash Flow (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Net Cash Flow for 16 consecutive years, with -$283.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 636.31% to -$283.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.6 million, a 916.31% increase, with the full-year FY2025 number at $20.6 million, up 916.31% from a year prior.
  • Net Cash Flow was -$283.2 million for Q4 2025 at Halozyme Therapeutics, down from $357.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $357.8 million in Q3 2025 to a low of -$373.0 million in Q4 2021.
  • A 5-year average of -$589100.0 and a median of $11.2 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: soared 2390.17% in 2021, then plummeted 15489.59% in 2023.
  • Halozyme Therapeutics' Net Cash Flow stood at -$373.0 million in 2021, then surged by 123.34% to $87.0 million in 2022, then tumbled by 279.07% to -$155.9 million in 2023, then surged by 75.32% to -$38.5 million in 2024, then crashed by 636.31% to -$283.2 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Net Cash Flow are -$283.2 million (Q4 2025), $357.8 million (Q3 2025), and -$114.5 million (Q2 2025).